tbuckley/cabot-search huggingface dataset:
Scoring System To Predict the Risk of Early Death during Induction Chemotherapy for Primary Acute Myeloid Leukemia (AML).
Authors: I. Sánchez-Ortega, D. Valcárcel, S. Brunet, Jordi Esteve, J. Berlanga, Josep-Maria Ribera, M. Tormo, J. Bueno, P. Torres, J. Guardia, M.P. Queipo de Llano, Juan Besalduch, A. Llorente, C. Pedro, J.M. Sánchez, J.M. Moraleda, J.M. Martí, J. Bargay, L.L. Font, P. Vivancos, D. Hernández, Emili Montserrat, Jorge Sierra
Journal: Blood (2006)
The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party
Authors: Christof Scheid, Liesbeth de Wreede, Anja van Biezen, Gudrun Göhring, Christian Koenecke, Liisa Violin, Johan Maertens, Jürgen Finke, Nicolaas PM Schaap, Jakob Passweg, Gerard Socie, Dietrich Beelen, Jan Cornelissen, Theo M. de Witte, Nikolaus Kroeger
Journal: Blood (2013)
Association between preanalytical factors and tumor mutational burden estimated by NGS-based multiplex gene panel assay
Authors: Quy Pham Nguyen, Masashi Kanai, Takayuki Kou, Tomohiro Kondo, Yoshihiro Yamamoto, Junichi Matsubara, Akinori Hiroshima, Hiroaki Mochizuki, Tomohiro Sakuma, Keita Fukuyama, Shigemi Matsumoto, Manabu Muto
Journal: Annals of Oncology (2019)
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia
Authors: Jean Grisouard, Mario Ojeda-Uribe, Renate Looser, Hui Hao-Shen, Pontus Lundberg, Adrian Duek, Eric Jeandidier, Axel Karow, Radek C. Skoda
Journal: Blood (2013)
Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score
Authors: Chetasi Talati, Andrew Kuykendall, Jori Kaplan, Jose D Sandoval-Sus, Samir Dalia, Bijal D. Shah, Celeste M. Bello, Farhad Khimani, Paul A. Chervenick, Ernesto Ayala, Frederick L. Locke, Mohamed A Kharfan-Dabaja, Eduardo M. Sotomayor, Lubomir Sokol, Julio C. Chavez
Journal: Blood (2016)
VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma
Authors: Min Kyoung Kim, Cheolwon Suh, Hyun Sook Chi, Hee Soon Cho, Kyung Hee Lee, Gyeong-Won Lee, In-Suk Kim, Hyeon Seok Eom, Sun-Young Kong, Sung Hwa Bae, Hun-Mo Ryoo, Yeung-Chul Mun, Hwasoon Chung, Myung Soo Hyun
Journal: Blood (2010)
Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial
Authors: Andrzej J Jakubowiak, Dominik Dytfeld, Sundar Jagannath, David H. Vesole, Tara B. Anderson, Brian K. Nordgren, Daniel Lebovic, Keith E. Stockerl-Goldstein, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Akari M. Dollard, Robert Ott, Susan L. Kelley, Jennifer Barrickman, Michael Kauffman, Ravi Vij
Journal: Blood (2010)
γH2AX Foci Increase Across the Spectrum from Myelodysplastic Syndromes to Acute Myeloid Leukemias and Co-Localize with 53BP1 in Specific Patterns in the Context of an Impaired DNA Damage Response
Authors: Henning D Popp, Susanne Brendel, Nicole Naumann, Thomas Henzler, Wolf-Karsten Hofmann, Alice Fabarius
Journal: Blood (2016)
Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)
Authors: Kelly J. Norsworthy, Alexander E Perl, Martin Carroll, Selina M. Luger, Kenneth S. Bauer, Michael L. Tidwell, Dina Ioffe, Maria R. Baer, Edward A. Sausville, Ivana Gojo
Journal: Blood (2011)
MCL-1 Critically Regulates Survival Of T-Lymphocyte Non-Hodgkin Lymphoma
Authors: Sabine Spinner, Kelly Gemma, Marco Herold, Konstanze Pechloff, Giuliano Crispatzu, Jürgen Ruland, Marco Herling, Christian Peschel, Andreas Strasser, Philipp J. Jost
Journal: Blood (2013)
ETV6 Regulates Pax5 Expression in Early B Cell Development
Authors: Courtney L. Jones, Gregory Kirkpatrick, Courtney Fleenor, Welsh Seth, Leila J Noetzli, Susan Fosmire, Dmitry Baturin, Xiayuan Liang, Giovanny Hernandez, Eric Martin Pietras, Craig T Jordan, Jesse W Rowley, Jorge Di Paola, James R. Hagman, Christopher C. Porter
Journal: Blood (2016)
Cytomegalovirus Reactivation Shapes NK Cells Diversity Following Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Li Li, Muharrem Muftuoglu, Han Chen, Duncan Mak, Elif Gokdemir, Hila Shaim, Jared Burks, May Daher, Nobuhiko Imahashi, Mayela Carolina Mendt Vilchez, Rafet Basar, David Marin, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2016)
Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML
Authors: Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu, Debra P. Ritzwoller
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Oral tyrosine kinase inhibitors (TKIs) have been the standard of care for chronic myeloid leukemia (CML) since 2001. However, few studies have evaluated changes in the treatment landscape of CML over time. This study assessed the long-term treatment patterns of oral anticancer therapies among patients with CML. Methods: This retrospective cohort study included patients newly diagnosed with CML between January 1, 2000, and December 31, 2016, from 10 integrated healthcare systems. The proportion of patients treated with 5 FDA-approved oral TKI agents—bosutinib, dasatinib, imatinib, nilotinib, and ponatinib—in the 12 months after diagnosis were measured, overall and by year, between 2000 and 2017. We assessed the use of each oral agent through the fourth-line setting. Multivariable logistic regression estimated the odds of receiving any oral agent, adjusting for sociodemographic and clinical characteristics. Results: Among 853 patients with CML, 81% received an oral agent between 2000 and 2017. Use of non-oral therapies decreased from 100% in 2000 to 5% in 2005, coinciding with imatinib uptake from 65% in 2001 to 98% in 2005. Approximately 28% of patients switched to a second-line agent, 9% switched to a third-line agent, and 2% switched to a fourth-line agent. Adjusted analysis showed that age at diagnosis, year of diagnosis, and comorbidity burden were statistically significantly associated with odds of receiving an oral agent. Conclusions: A dramatic shift was seen in CML treatments away from traditional, nonoral chemotherapy toward use of novel oral TKIs between 2000 and 2017. As the costs of oral anticancer agents reach new highs, studies assessing the long-term health and financial outcomes among patients with CML are warranted.
Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in β-Thalassemia
Authors: Patrick B. Walter, Nick Slater, Paul Harmatz, Annie Higa, Vivian Ng, Marcels Weyhmiller, Patricia Evans, John B Porter, Nancy Sweeters, Jackson Price, David Killilea, Lynne Neumayr, Ashutosh Lal, Elliott Vichinsky
Journal: Blood (2015)
Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma
Authors: Neelima Vidula, Borko Jovanovic, Jane N. Winter, Jayesh Mehta, Seema Singhal, Stephanie F. Williams, Olga Frankfurt, Jessica K. Altman, Joanne Monreal, Andrew M. Evens, Leo I. Gordon
Journal: Blood (2011)
Hepatitis B and C Virus Infections Are Not Associated With Worse Clinical Outcomes After Autologous Stem Cell Transplantation: On Behalf Of The Adult Lymphoma Working Group Of The Japan Society For Hematopoietic Cell Transplantation (JSHCT)
Authors: Harumi Kato, Dai Chihara, Koji Kato, Sung-Won Kim, Takehiko Mori, Masashi Sawa, Yuki Ohno, Hisako Hashimoto, Masayuki Hino, Koji Iwato, Takaaki Chou, Hisashi Sakamaki, Ritsuro Suzuki, Junji Suzumiya
Journal: Blood (2013)
Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
Authors: Charalampia Kyriakou, Philip Murphy, Maria Teresa Petrucci, Pamela Bacon, Philip Lewis, Hélène Gilet, Benoit Arnould, Isabelle Vande Broek, Xavier Leleu
Journal: Blood (2015)
Identifying significantly impacted pathways: a comprehensive review and assessment
Authors: Tuan-Minh Nguyen, Adib Shafi, Tin Nguyen, Sorin Draghici
Journal: Genome biology (2019)

Abstract Background Many high-throughput experiments compare two phenotypes such as disease vs. healthy, with the goal of understanding the underlying biological phenomena characterizing the given phenotype. Because of the importance of this type of analysis, more than 70 pathway analysis methods have been proposed so far. These can be categorized into two main categories: non-topology-based (non-TB) and topology-based (TB). Although some review papers discuss this topic from different aspects, there is no systematic, large-scale assessment of such methods. Furthermore, the majority of the pathway analysis approaches rely on the assumption of uniformity of p values under the null hypothesis, which is often not true. Results This article presents the most comprehensive comparative study on pathway analysis methods available to date. We compare the actual performance of 13 widely used pathway analysis methods in over 1085 analyses. These comparisons were performed using 2601 samples from 75 human disease data sets and 121 samples from 11 knockout mouse data sets. In addition, we investigate the extent to which each method is biased under the null hypothesis. Together, these data and results constitute a reliable benchmark against which future pathway analysis methods could and should be tested. Conclusion Overall, the result shows that no method is perfect. In general, TB methods appear to perform better than non-TB methods. This is somewhat expected since the TB methods take into consideration the structure of the pathway which is meant to describe the underlying phenomena. We also discover that most, if not all, listed approaches are biased and can produce skewed results under the null.
Correlation of Quantitative Gene Expression by RQ-PCR with Clinical and Biologic Factors in Mantle Cell Lymphoma.
Authors: Dirk Kienle, Doreen Saupe, Tiemo Katzenberger, Axel Benner, Elke Leupolt, Andreas Rosenwald, German Ott, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2004)
Anthocyanins Inhibit Platelet Activation and Attenuate Thrombus Growth In Both Human and Murine Thrombosis Models
Authors: Yan Yang, Zhenyin Shi, Adili Reheman, Wuxun Jin, Conglei Li, Guangheng Zhu, Yiming Wang, John J. Freedman, Wenhua Ling, Heyu Ni
Journal: Blood (2010)
Minimally invasive resection of brain metastases
Authors: Isaac Phang, John Leach, James Leggate, Konstatina Karabatsou, David Coope, Pietro D’Urso
Journal: Neuro-Oncology (2019)

Abstract Minimally invasive resection of brain metastases aims to maximize resection while minimizing brain trauma. Patients with one or more metastases resection following neuro-oncology multidisciplinary meeting discussion from Sep 2014 to Oct 2018 with pre- and post-operative MRI were included. All patients including posterior fossa metastases or multiple metastases were positioned supine. Hair was not shaved. Volumetric post-contrast T1 MRI was used for incision planning and neuronavigation. The craniotomy site was tailored to tumor depth according to keyhole principles and ranged between 2 to 3cm. Intraoperative monitoring and awake mapping were carried out in selected cases. Out of 320 consecutive patients with brain metastases, 44 patients were identified as suitable for minimally invasive resection. 9 had no post-operative imaging and were excluded. There were 39 metastases in 35 patients. There were 18 cerebellar metastases, 9 frontal, 5 parietal, 3 occipital, 2 temporal, 1 intraventricular and 1 basal ganglia. Median length of stay was days (range: 1 – 24). Average tumor volume was 54.7cm3 (range: 10 – 240cm3). Endoscopic assistance was used in 4 patients. Median performance status improved from 2 to 1(range: pre-operative: 0 – 4; post-operative: 0 – 2). Median survival was 14.7 months. Minimally invasive resection of brain metastasis is safe and effective and in selected cases confers advantages compared to standard techniques.
Systematic Evaluation of Preclinical Genetically Determined Vs. "Stochastic"/Transient Resistance to High-Dose Melphalan Treatment in Multiple Myeloma
Authors: Paul J. Hengeveld, Geoffrey M. Matthews, Yiguo Hu, Michal Sheffer, Megan A. Bariteau, Haley I. Poarch, Eugen Dhimolea, Constantine S Mitsiades
Journal: Blood (2015)
No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries
Authors: Niklas Gunnarsson, Martin Höglund, Leif Stenke, Fredrik Sandin, Magnus Bjorkholm, Arta Dreimane, Mats Lambe, Berit Markevärn, Ulla Olsson-Strömberg, Hans Wadenvik, Johan Richter, Anders Själander
Journal: Blood (2016)
Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation
Authors: Cristina Calderón Cabrera, Jose F Falantes, Marina Gómez, Rocío Parody, Francisco J Márquez Malaver, María L Martino, José González, Isabel Montero, Ildefonso Espigado, Jose Antonio Pérez-Simón
Journal: Blood (2013)
Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival
Authors: Frederick Lansigan, Wilson L Davis, Nancy Kuemmerle, Leslie E Lupien, Valeriya Posternak, Prabhjot Kaur, Nicole C Smits, Ravi Dashnamoorthy, Andrew M. Evens, William B Kinlaw
Journal: Blood (2012)
Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)
Authors: Lin Tang, Anna Dolnik, Kyle J. MacBeth, Hervé Dombret, John F. Seymour, Mark D. Minden, Richard M. Stone, C.L. Beach, Hartmut Döhner, Lars Bullinger
Journal: Blood (2016)
Combination of Intensive Chemotherapy and Imatinib (IDEAMOP Regimen) for the Treatment of Newly Diagnosed BCR-ABL Positive Acute Lymphoblastic Leukemia; Excellent Efficacy without Increasing Toxicity.
Authors: Masamitsu Yanada, Nobuhiko Emi, Noriko Usui, Jin Takeuchi, Isamu Sugiura, Makoto Takeuchi, Tohru Kobayashi, Fumiharu Yagasaki, Shigeki Ohtake, Keitaro Matsuo, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2004)
Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients
Authors: Salomon Manier, Erica N Boswell, Siobhan Glavey, Antonio Sacco, Patricia Maiso, Yuji Mishima, Yosra Aljaway, Ranjit Banwait, Wenjing Zhang, Yu Zhang, Ilyas Sahin, Michele Moschetta, Yong Zhang, Michaela R Reagan, John M. Asara, Xavier Leleu, Aldo M Roccaro, Irene M. Ghobrial
Journal: Blood (2013)
Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Authors: Jean-Baptiste Fraison, Arsène Mekinian, Eric Grignano, Jean-Emmanuel Kahn, Jean-Benoît Arlet, Olivier Decaux, Denis Guillaume, Anne-Laure Buchdahl, Mohamed Omouri, Gwenola Maigne, Achille Aouba, Nathalie Leon, Sabine Berthier, Eric Liozon, Sophie Park, Claude Gardin, Olivier Lortholary, Julien Rossignol, Pierre Fenaux, Olivier Fain, Thorsten Braun
Journal: Blood (2015)
The efficacy and safety of neoadjuvant mFOLFOXIRI and XELOX for locally advanced rectal cancer: A retrospective study
Authors: Hiroyuki Kodama, Tetsuji Terazawa, Hiroki Yukami, Masahiko Aoki, Ken Asaishi, Toshifumi Yamaguchi, Takayuki Kii, Masahiro Goto, Keitarou Tanaka, Jyunji Okuda, Kazuhide Higuchi
Journal: Annals of Oncology (2019)
Characterisation of the invasive tumour niche using astrocyte-glioblastoma organoids and decellularised human brain
Authors: Mohammed Diksin, Jonathan Rowlinson, Alexandar Kondrashov, Chris Denning, Jamie Hughes, Tim Constantin-Teodo, Wei Cui, Chris Gell, David Onion, Nicola Croxall, Stuart Smith, Ruman Rahman
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma therapeutic challenges are in considerable part due to myriad survival adaptations and mechanisms, which allow malignant cells to repurpose signalling pathways within discreet microenvironments. These Darwinian adaptations facilitate invasion into brain parenchyma and perivascular space or promote evasion from repressive factors that represent anti-cancer defence mechanisms. We hypothesised that pre-clinical modelling of glioma invasion by recapitulating early events occurring immediately after surgery at the glioblastoma invasive margin, could reveal the cross-talk between malignant cells and the surrounding healthy astrocytes, which facilitates tumour recurrence. We first generated transgenic H1-derived neural stem cells using CRISPR/Cas9-mediated knock-in of the YFP reporter gene under the control of the GFAP promoter. Reproducible ultrahigh-throughput AggreWells™ (19,200 micro-wells per 24-well plate) were used to create astrocyte-glioblastoma organoids, which we term ‘Gliomasphere Matrices’. YFP-labelled astrocytes were co-cultured with 10 treatment-naïve patient-derived cell lines isolated from the 5-aminolevulinic (5ALA)-determined glioblastoma invasive margin. Co-cultures were seeded upon on a sequentially constructed, time-of-flight secondary ion mass spectrometry (ToF-SIMS)-characterised 3D scaffold, composed of decellularised human brain extract with defined PEGDA hydrogel. YFP-astrocytes were purified from each of the 10 Gliomasphere Matrices using fluorescence-activated cell sorting (FACS) after 6- and 10-days co-culture. RNAseq profiling to address both putative astrocytic reprogramming by invasive glioblastoma cells and gene expression changes intrinsic to tumour cells will be discussed in relation to RNAseq data from patient-derived 5ALA FACS-purified glioblastoma invasive margin tissue. This novel multi-faceted model offers a unique opportunity to recapitulate early molecular cross-talk which facilitates glioblastoma recurrence and may be utilised for high-throughput drug screening.
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
Authors: Christopher L. Bowlus, Paul J. Pockros, Andreas E. Kremer, Albert Parés, Lisa M. Forman, Joost P.H. Drenth, Stephen D. Ryder, Luigi Terracciano, Yuying Jin, Alexander Liberman, Richard Pencek, Uche Iloeje, Leigh MacConell, Pierre Bedossa
Journal: Clinical Gastroenterology and Hepatology (2019)
Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)
Authors: Jian Yu, Liguang Chen, George F. Widhopf, Suping Zhang, Bing Cui, Rongrong Wu, Ling Zhang, Thomas J. Kipps
Journal: Blood (2015)
Clinical Utility of Next-Generation Sequencing-Based Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Authors: Yuko Sekiya, Yusuke Okuno, Hideki Muramatsu, Atsushi Narita, Kyogo Suzuki, Xinan Wang, Nozomu Kawashima, Yinyan Xu, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Yoshiyuki Takahashi, Koji Kato, Seiji Kojima
Journal: Blood (2015)
A Subnuclear Targeting Defective Mutant of Runx1 Uncouples the Roles of Runx1 In Embryonic Development and Adult Definitive Hematopoiesis
Authors: Christopher R Dowdy, Dana Frederick, Sayyed K. Zaidi, Jane B. Lian, J. van Wijnen, Janet L. Stein, Gary S. Stein
Journal: Blood (2011)
CLL Stereotyped IGHV-D-J Rearrangements Can Be Detected Throughout Normal B-Cell Developmental Stages in Aged People When Using Ultra-Deep, Next Generation Sequencing Techniques
Authors: Stefano Vergani, Davide Bagnara, Andrea Nicola Mazzarello, Gerardo Ferrer, Sophia Yancopoulos, Kostas Stamatopoulos, Nicholas Chiorazzi
Journal: Blood (2016)
A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages
Authors: Nikita Joshi, Satoshi Watanabe, Rohan Verma, Renea P. Jablonski, Ching-I Chen, Paul Cheresh, Nikolay S. Markov, Paul A. Reyfman, Alexandra C. McQuattie-Pimentel, Lango Sichizya, Ziyan Lu, Raul Piseaux-Aillon, David Kirchenbuechler, Annette S. Flozak, Cara J. Gottardi, Carla M. Cuda, Harris Perlman, Manu Jain, David W. Kamp, G.R. Scott Budinger, Alexander V. Misharin
Journal: European Respiratory Journal (2019)

Ontologically distinct populations of macrophages differentially contribute to organ fibrosis through unknown mechanisms. We applied lineage tracing, single-cell RNA sequencing and single-molecule fluorescence in situ hybridisation to a spatially restricted model of asbestos-induced pulmonary fibrosis. We demonstrate that tissue-resident alveolar macrophages, tissue-resident peribronchial and perivascular interstitial macrophages, and monocyte-derived alveolar macrophages are present in the fibrotic niche. Deletion of monocyte-derived alveolar macrophages but not tissue-resident alveolar macrophages ameliorated asbestos-induced lung fibrosis. Monocyte-derived alveolar macrophages were specifically localised to fibrotic regions in the proximity of fibroblasts where they expressed molecules known to drive fibroblast proliferation, including platelet-derived growth factor subunit A. Using single-cell RNA sequencing and spatial transcriptomics in both humans and mice, we identified macrophage colony-stimulating factor receptor (M-CSFR) signalling as one of the novel druggable targets controlling self-maintenance and persistence of these pathogenic monocyte-derived alveolar macrophages. Pharmacological blockade of M-CSFR signalling led to the disappearance of monocyte-derived alveolar macrophages and ameliorated fibrosis. Our findings suggest that inhibition of M-CSFR signalling during fibrosis disrupts an essential fibrotic niche that includes monocyte-derived alveolar macrophages and fibroblasts during asbestos-induced fibrosis.
High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM).
Authors: Jean El-Cheikh, Mauricette Michallet, Arnon Nagler, Hugues de Lavallade, Frank E. Nicolini, Avichai Shimoni, Catherine Faucher, Mohamad Sobh, Daniela Revesz, Izhar Hardan, Sabine Furst, Didier Blaise, Mohamad Mohty
Journal: Blood (2007)
Apparent Involvement Of The Interferon, RNA Processing, and Wnt Signaling Pathways In Monoclonal B Lymphocytosis
Authors: Xiao-Jie Yan, Claudia Fazi, Scarfo Lydia, Wentian Li, Jonathan E. Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Kanti R. Rai, Paolo Ghia, Nicholas Chiorazzi
Journal: Blood (2013)
Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.
Authors: Michelle A. Fanale, Chao-Ming Lai, Peter McLaughlin, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Felipe Samaniego, Maria Alma Rodriguez, Sattva S. Neelapu, Jatin J Shah, Larry Kwak, Wenli Dong, Valerie Reed, Bouthaina S. Dabaja, Uday Popat, Anas Younes
Journal: Blood (2010)
Mitochondrial Respiratory Chain Complex III Causes Genomic Instability In CML-CP.
Authors: Piotr Kopinski, Margaret Nieborowska-Skorska, Grazyna Hoser, Danielle Ngaba, Regina Ray, Mateusz Koptyra, Elisabeth Bolton, Ilona Seferynska, Tomasz Stoklosa, Artur Slupianek, Mamatha R. Reddy, Martin Sattler, Tomasz Skorski
Journal: Blood (2010)
Treatment Stratification According to Early Response to Mega-CHOP, Based on CT and Gallium 67 Scan (G67S) with or without IFE Salvage Therapy Followed by Peripheral Autologous Stem Cell Transplant (PBSCT) in Patient with Poor Prognosis Aggressive Lymphoma. A Preliminary Report from a Prospective GEL/TAMO Trial.
Authors: Eulogio Conde, Reyes Arranz, José Rodriguez, María L. Gutierrez, Carlos Grande, Marco Gandarillas, Carmen Albo, José L. Bello, Sebastián Garzón, Miguel T. Hernández, José A. García-Vela, Pascual Fernández, María L. Amigo, Dolores Caballero
Journal: Blood (2005)